Any feedback?
Literature summary for 1.14.14.B9 extracted from
- Oxygenation of polyunsaturated long chain fatty acids by recombinant CYP4F8 and CYP4F12 and catalytic importance of Tyr-125 and Gly-328 of CYP4F8 (2005), Arch. Biochem. Biophys., 441, 174-181.
Application
| Application | Comment | Organism |
|---|---|---|
| medicine | missense mutation Y125F in substrate recognition site-1 occurs naturally in low frequency. The variant oxidizes two prostaglandin H2 analogs U-51605 and U-44069, but 4,7,10,13,16-(Z)-docosatetraenoic acid and 4,7,10,13,16-(Z)-docosapentaenoic acid are not oxidized | Homo sapiens |
Cloned(Commentary)
| Cloned (Comment) | Organism |
|---|---|
| expression in Escherichia coli, Saccharomyces cerevisiae | Homo sapiens |
Protein Variants
| Protein Variants | Comment | Organism |
|---|---|---|
| G328E | mutant oxidizes prostaglandin H2 analogs U-51605 and U-44069 as recombinant CYP4F8, but the hydroxylation of arachidonic acid is shifted from C-18 to C-19 | Homo sapiens |
| Y125F | missense mutation in substrate recognition site-1, occuring naturally in low frequency. The variant oxidizes prostaglandin H2 analogs U-51605, i.e. 9,11-diazo-prostadienoic acid, and U-44069, i.e. 9alpha,11alpha-epoxymethano-prostaglandin H2 in omega2 and omega3 position, but 4,7,10,13,16-(Z)-docosatetraenoic acid and 4,7,10,13,16-(Z)-docosapentaenoic acid are not oxidized | Homo sapiens |
Localization
| Localization | Comment | Organism | GeneOntology No. | Textmining |
|---|---|---|---|---|
| microsome | - |
Homo sapiens | - |
- |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Homo sapiens | P98187 | - |
- |
| Homo sapiens | Q9HCS2 | - |
- |
Reaction
| Reaction | Comment | Organism | Reaction ID |
|---|---|---|---|
| (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate + [reduced NADPH-hemoprotein reductase] + O2 = (4Z,7Z,10Z,13Z,16Z)-19,20-epoxydocosa-4,7,10,13,16-pentaenoate + [oxidized NADPH-hemoprotein reductase] + H2O | (1) | Homo sapiens | |
| (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate + [reduced NADPH-hemoprotein reductase] + O2 = (4Z,7Z,10Z,16Z,19Z)-13,14-epoxydocosa-4,7,10,16,19-pentaenoate + [oxidized NADPH-hemoprotein reductase] + H2O | (2) | Homo sapiens | |
| (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate + [reduced NADPH-hemoprotein reductase] + O2 = (4Z,7Z,13Z,16Z,19Z)-10,11-epoxydocosa-4,7,13,16,19-pentaenoate + [oxidized NADPH-hemoprotein reductase] + H2O | (3) | Homo sapiens |
Substrates and Products (Substrate)
| Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
|---|---|---|---|---|---|---|
| (4Z,7Z,10Z,13Z,16Z)-docosa-4,7,10,13,16-pentaenoate + [reduced NADPH-hemoprotein reductase] + O2 | - |
Homo sapiens | (4Z,7Z,10Z,13Z,16Z)-20-hydroxydocosa-4,7,10,13,16-pentaenoate + [oxidized NADPH-hemoprotein reductase] + H2O | main product, plus minor amounts of 21-hydroxy-4,7,10,13,16-(Z)-docosapentaenoic acid, no significant formation of dihydroxycompounds | ? |  |
| (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate + [reduced NADPH-hemoprotein reductase] + O2 | - |
Homo sapiens | (4Z,7Z,10Z,13Z,16Z)-19,20-epoxydocosa-4,7,10,13,16-pentaenoate + [oxidized NADPH-hemoprotein reductase] + H2O | formation of 19,20-epoxydocosapentaenoic acid, 16,17-epoxydocosahexaenoic acid, 13,14-epoxydocosahexaenoic acid, and 10,11-epoxydocosahexaenoic acid, no significant formation of 21-hydroxy- or 22-hydroxydocosahexaenoic acid. Reaction is catalyzed by both isoforms CYP4F8 and CYP4F12 | ? | |
| (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate + [reduced NADPH-hemoprotein reductase] + O2 | - |
Homo sapiens | (4Z,7Z,10Z,16Z,19Z)-13,14-epoxydocosa-4,7,10,16,19-pentaenoate + [oxidized NADPH-hemoprotein reductase] + H2O | formation of 19,20-epoxydocosapentaenoic acid, 16,17-epoxydocosahexaenoic acid, 13,14-epoxydocosahexaenoic acid, and 10,11-epoxydocosahexaenoic acid, no significant formation of 21-hydroxy- or 22-hydroxydocosahexaenoic acid. Reaction is catalyzed by both isoforms CYP4F8 and CYP4F12 | ? | |
| (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate + [reduced NADPH-hemoprotein reductase] + O2 | - |
Homo sapiens | (4Z,7Z,13Z,16Z,19Z)-10,11-epoxydocosa-4,7,13,16,19-pentaenoate + [oxidized NADPH-hemoprotein reductase] + H2O | formation of 19,20-epoxydocosapentaenoic acid, 16,17-epoxydocosahexaenoic acid, 13,14-epoxydocosahexaenoic acid, and 10,11-epoxydocosahexaenoic acid, no significant formation of 21-hydroxy- or 22-hydroxydocosahexaenoic acid. Reaction is catalyzed by both isoforms CYP4F8 and CYP4F12 | ? | |
| (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoate + [reduced NADPH-hemoprotein reductase] + O2 | - |
Homo sapiens | (7Z,10Z,13Z,16Z)-19,20-epoxydocosa-7,10,13,16-tetraenoate + [oxidized NADPH-hemoprotein reductase] + H2O | formation of 19,20-epoxydocosatetraenoic acid, 16,17-epoxydocosatetraenoic acid, 13,14-epoxydocosatetraenoic acid, and 10,11-epoxydocosatetraenoic acid, no formation of 21-hydroxy- or 22-hydroxydocosapentaenoic acid | ? | |
| (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoate + [reduced NADPH-hemoprotein reductase] + O2 | - |
Homo sapiens | (7Z,10Z,13Z,19Z)-16,17-epoxydocosa-7,10,13,19-tetraenoate + [oxidized NADPH-hemoprotein reductase] + H2O | formation of 19,20-epoxydocosapentaenoic acid, 16,17-epoxydocosapentaenoic acid, 13,14-epoxydocosapentaenoic acid, and 10,11-epoxydocosapentaenoic acid, no formation of 21-hydroxy- or 22-hydroxydocosapentaenoic acid | ? | |
| (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoate + [reduced NADPH-hemoprotein reductase] + O2 | - |
Homo sapiens | (7Z,13Z,16Z,19Z)-10,11-epoxydocosa-7,13,16,19-tetraenoate + [oxidized NADPH-hemoprotein reductase] + H2O | formation of 19,20-epoxydocosapentaenoic acid, 16,17-epoxydocosapentaenoic acid, 13,14-epoxydocosapentaenoic acid, and 10,11-epoxydocosapentaenoic acid, no formation of 21-hydroxy- or 22-hydroxydocosapentaenoic acid | ? | |
| arachidonic acid + [reduced NADPH-hemoprotein reductase] + O2 | - |
Homo sapiens | 18-hydroxyarachidonic acid + [oxidized NADPH-hemoprotein reductase] + H2O | hydroxylation at C-18 | ? | |
Synonyms
| Synonyms | Comment | Organism |
|---|---|---|
| CYP4F12 | - |
Homo sapiens |
| CYP4F8 | - |
Homo sapiens |
Temperature Optimum [°C]
| Temperature Optimum [°C] | Temperature Optimum Maximum [°C] | Comment | Organism |
|---|---|---|---|
| 37 | - |
assay at | Homo sapiens |
pH Optimum
| pH Optimum Minimum | pH Optimum Maximum | Comment | Organism |
|---|---|---|---|
| 7.4 | - |
assay at | Homo sapiens |
Cofactor
| Cofactor | Comment | Organism | Structure |
|---|---|---|---|
| NADPH | - |
Homo sapiens | |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
